Genetic Signatures Ltd. (AU:GSS) has released an update.
Genetic Signatures Ltd. reported a third-quarter revenue of $1.7 million, a dip due to seasonal fluctuations and regulatory reviews, but closed the period with a strong cash balance of $20.3 million following a successful $15.9 million capital raise. The Australian TGA has authorized the supply of the company’s redesigned EasyScreen™ Respiratory Detection Kit, positioning it for the upcoming flu season, and preparations are underway for the anticipated U.S. launch of their gastrointestinal kit pending FDA approval.
For further insights into AU:GSS stock, check out TipRanks’ Stock Analysis page.
